Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis

Respiratory Care

Volumn 42, Issue 2, 1997, Pages 206-213

  DeAbate, C Andrew ^a   Russell, Melvin ^b   McElvaine, Phillip ^c   Faris, Henry ^d   Upchurch, John ^e   Fowler, Cynthia L ^a   Polak, Elaine M ^a   Morgan, Nancy S ^a  

^a Medical Research Centers   (United States)

^b Community Medical Arts Center ^*  (United States)

^c Woodward Medical Center ^*

^d St Vincent's Adult Medical Clinic   (United States)

^e R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME AXETIL; LEVOFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; VAGINITIS;

EID: 0031024361     PISSN: 00989142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47(4):677-700. See the published erratum Drugs 1994;48(1):132.
2. Fu KP, Lafredo SC, Foleno BD, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In vitro and in vivo antimicrobial activities of levofloxacin (1-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992;36(4):860-866. See the published erratum Antimocrob Agents Chemother 1992;36(8):1797.
3. Kayser FH. Changes in the spectrum of organisms causing respiratory tract infections: a review. Postgrad Med J 1992;68(Suppl 3):S17-S23.
4. Okazaki O, Kojima C, Hakusui H, Nakashima M. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother 1991;35(10):2106-2109.
5. Chien S-C, Rogge MC, Gisclon LG, et al. The pharmacokinetic profile of levofloxacin following once daily 500 mg oral or intravenous doses. Presented, in part, at the 4th International Symposium on New Quinolones, Aug. 27-29, 1992, Munich, Germany (Abstract #113).
6. Nagai H, Yamasaki T, Masuda M, Goto Y, Tasiro T, Nasu M. Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 1993;45(Suppl 3):259.
7. Nakamori Y, Tsuboi E, Narui K, Nakatani T, Nakata K, Sugi H. Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections. Jpn J Antibiot. 1992;45 (5):539-547.
8. Tanaka K, Iwamoto M, Maesaki S, Koga H, Kohno S, Hara K, et al. Laboratory and clinical studies on levofloxacin. Jpn J Antibiot 1992;45(5):548-556.
9. Habib MP, Gentry LO, Rodriguez-Gomez G, Morowitz W, Polak E, Rae JK, et al. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute exacerbations of chronic bronchitis. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, September 1996.
10. Fogarty CM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults. Presented at a satellite symposium of the 19th International Congress of Chemotherapy, Montreal, Canada, July 16-21, 1995.
11. File TM. Community-acquired pneumonia: update on therapeutic options. Presented at a satellite symposium of the 19th International Congress of Chemotherapy, Montreal, Canada, July 16-21, 1995.
12. Sydnor TA, Scheld WM, Gwaltney JM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of acute bacterial sinusitis in adults. Presented at a satellite symposium of the 19th International Congress of Chemotherapy, Montreal, Canada, July 16-21, 1995.
13. Landau Z, Schlaffer F, Pitlik S. Cefuroxime axetil vs. augmentin for the treatment of acute bronchitis and exacerbation of chronic obstructive pulmonary disease. Isr J Med Sci 1992;28(11):797-799.
14. Pelletier LL Jr. Review of the experience with cefprozil for the treatment of lower respiratory tract infections. Clin Infect Dis 1992;14(Suppl 2): S238-245.
15. Shah SH, Shah IS, Turnbull G, Cunningham K. Cefuroxime axetil in the treatment of bronchitis: comparison with amoxycillin in a multicentre study in general practice patients. Br J Clin Pract 1994;48 (4):185-189.
16. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Disease Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(Suppl 1):S62-88.
17. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34(11): 2075-2080.
18. Emergence of penicillin-resistant Streptococcus pneumoniae - Southern Ontario, Canada 1993-1994. MMWR Morb Mortal Wkly Rep 1995:44(11):207-215.
19. Defining the public health impact of drug-resistant Streptococcus pneumoniae: Report of a working group. MMWR Morb Mortal Wkly Rep 1996;45(RR-1 Suppl):1-20.
20. Soejima R, Kawane J, Okimoto S, et al. Comparative study of levofloxacin and ofloxacin in chronic respiratory tract infections by the double-blind method. Chemotherapy 1992;40(Suppl 3):97-120.
21. Saito A, Irabu Y, Fukukara H, et al. Dose finding comparative study on levofloxacin in chronic respiratory tract infection. Chemotherapy 1992;40(suppl 3):75-96.
22. Brambilla C, Kastanakis S, Knight S, Cunningham. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992;11(2):118-124.